TP53 and medulloblastoma: In the preclinical setting, AZD1775 has been shown to act synergistically with a range of chemotherapy agents in p53-deficient tumors and with ionizing radiation or cisplatin in medulloblastoma cells, irrespective of p53 phenotype [101].